EAACI与WAO严重过敏反应指南药物急救管理解读及证据分析  

Interpretation and Citation Analysis of Drug Emergency Management in EAACI and WAO Clinical Guidelines for Anaphylaxis

作　　者：张紫薇 骆兵 葛卫红[1] 汪小海[3] ZHANG Ziwei;LUO Bing;GE Weihong;WANG Xiaohai(Department of Pharmacy,Nanjing Drum Tower Hospital Affiliated to Medical College of Nanjing University,Nanjing 210008,China;School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 210009,China;Department of Anesthesiology,Taikang Xianlin Drum Tower Hospital Affiliated to Medical College of Nanjing University,Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008 [2]中国药科大学基础医学与临床药学学院,南京210009 [3]南京大学医学院附属泰康仙林鼓楼医院麻醉科,南京210008

出　　处：《医药导报》2021年第11期1511-1516,共6页Herald of Medicine

摘　　要：严重过敏反应是一种临床急症,其患病率呈逐年上升趋势,处理不当可危及生命。近年来,世界各国陆续发布严重过敏反应指南,指南急救药物管理方案中的引文证据均支持将肾上腺素作为一线用药,而关于抗组胺药、肾上腺素能β2受体激动药和糖皮质激素的推荐意见有所不同。该文主要介绍2014年版欧洲变态反应与临床免疫学会(EAACI)严重过敏反应指南和2020年版世界过敏组织严重过敏反应指导意见(WAO)指南中严重过敏反应药物急救管理部分内容,对比分析其引文证据内容和质量水平,并补充最新研究证据,以期为严重过敏反应急救的规范用药提供参考。Anaphylaxis is a kind of clinical emergency,and its prevalence rate is increasing year by year,which can be life-threatening if not handled properly.In recent years,countries around the world have issued guidelines for anaphylaxis.The citation evidence in the emergency drug management program of the guidelines supports epinephrine as a first-line drug.The recommendations for antihistamines,adrenergicβ2 receptor agonists and glucocorticoids are different in these guidelines.In order to provide reference for the standardized use of drugs in the emergency treatment of anaphylaxis,this paper mainly introduces the contents of the emergency management of anaphylaxis in the 2014 EAACI guideline and 2020 WAO guideline,compares and analyzes the contents and quality of the citation evidence,and supplies the latest research evidence.

关 键 词：严重过敏反应 急救用药 指南 推荐意见 证据 

分 类 号：R976[医药卫生—药品] R969[医药卫生—药学]